Bronwyn Brophy

Bronwyn is the CEO of the Vitrolife Group, a world leading provider of medical devices and genetic services for the reproductive health industry. The company is headquartered in Gothenburg, Sweden and is listed on the NASDAQ Stockholm. It has over 1100 employees and a revenue of circa $360M. Prior to joining Vitrolife she served as the Global President for the Immunodiagnostics Division of Thermo Fisher Scientific based in Uppsala, Sweden. Bronwyn has over 25 years experience in the MedTech industry having also worked for Medtronic, Covidien, and Johnson & Johnson in a number of senior roles around the globe covering businesses including general surgery, women’s health, gastroenterology, cardiology and oncology. In terms of scope and scale she has had P & L responsibility for businesses ranging from $200M- $8BN in revenue. She has a strong track record in strategy development, accelerating profitable growth, leading M & A and also driving digital transformations. Bronwyn has led several large scale R & D programs, building out next generation platforms. She has worked in multiple regions globally and has experience driving geographic expansion in the U.S. and China. She has high credibility across the MedTech/Life science industry and is known for her integrity and honesty, always putting patients first. She is a purpose driven leader who builds strong followership and loyalty. Bronwyn was elected to the board of MedTech Europe in 2021 and served as Vice Chair of the Operations Management Committee. She holds a BA in International Business & Languages (Spanish, French) and an MBA from Dublin City University. Bronwyn completed the Harvard Preparing to be a Corporate Director Course in 2023.